Harvard Bioscience
HBIO
68 hedge funds and large institutions have $78.5M invested in Harvard Bioscience in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 19 increasing their positions, 30 reducing their positions, and 18 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
6% more capital invested
Capital invested by funds: $74M → $78.5M (+$4.5M)
0.28% more ownership
Funds ownership: 6.94% → 7.22% (+0.28%)
14% less funds holding
Funds holding: 79 → 68 (-11)
37% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 30
61% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 18
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $28K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
2C
272 Capital
Dallas,
Texas
|
+$3.63M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$1.68M |
| 3 |
AE
AMH Equity
Great Neck,
New York
|
+$1.56M |
| 4 |
MIM
Meros Investment Management
Dallas,
Texas
|
+$987K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$268K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$782K |
| 2 |
BlackRock
New York
|
-$712K |
| 3 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$709K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$691K |
| 5 |
MPAM
Monarch Partners Asset Management
Boston,
Massachusetts
|
-$462K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Lazard Asset Management
New York
| – | -$18K | -712 | Closed |
|
|
TRCT
77
Tower Research Capital (TRC)
New York
| – | -$9K | -376 | Closed |
|
78
Osaic Holdings
Scottsdale,
Arizona
| – | -$5K | -210 | Closed |
|
79
Simplex Trading
Chicago,
Illinois
| – | -$3.45K | -140 | -93% |
|
|
HI
80
Harbour Investments
Madison,
Wisconsin
| – | -$4K | -100 | Closed |
|
|
PGAM
81
Princeton Global Asset Management
Princeton,
New Jersey
| – | -$1K | -50 | Closed |
|
82
Citigroup
New York
| – | -$1K | -49 | Closed |
|
|
CUAMC
83
China Universal Asset Management Company
Shanghai,
China
| – | -$1K | -39 | Closed |
|
HBIO Hedge Fund Activity: Q4 2022 in Review
68 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q4 2022, worth a combined $78.5M — up 6.1% from $74M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of HBIO and 7 opened new positions — a net loss of 11 holders — while 30 trimmed existing stakes and 19 added.
The largest buyer was 272 Capital, adding an estimated $3.63M. The largest seller was Parkman Healthcare Partners, exiting entirely with an estimated $782K sold.
- 68 institutional investors held Harvard Bioscience (HBIO) as of Q4 2022, down from 79 in Q3 2022.
- Funds reported $78.5M of Harvard Bioscience stock for Q4 2022, up 6.1% quarter-over-quarter.
- 7 funds opened new Harvard Bioscience positions in Q4 2022 and 18 closed out, a net change of -11 holders.
- The largest Harvard Bioscience buyer in Q4 2022 was 272 Capital, an estimated $3.63M added.
- The largest Harvard Bioscience seller in Q4 2022 was Parkman Healthcare Partners, an estimated $782K sold.
Based on aggregated 13F filings for Q4 2022.